Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2008 by Chulalongkorn University.
Recruitment status was  Recruiting
Information provided by:
Chulalongkorn University Identifier:
First received: June 20, 2008
Last updated: June 23, 2008
Last verified: June 2008
To compare the efficacy, safety and tolerability of 0.05% topical cyclosporin eye drop to Refresh in moderate to severe dry eye patients. Null hypothesis is: there is no difference between these two groups.

Condition Intervention Phase
Dry Eye
Drug: 0.05% cyclosporin eye drop
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes

Resource links provided by NLM:

Further study details as provided by Chulalongkorn University:

Primary Outcome Measures:
  • Corneal and conjunctival staining score [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Schirmer 1 score [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 60
Study Start Date: June 2007
Estimated Study Completion Date: October 2008
Estimated Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
0.05% cyclosporin
Drug: 0.05% cyclosporin eye drop
bid dosage for 4 months
Active Comparator: B
Drug: 0.05% cyclosporin eye drop
bid dosage for 4 months

Detailed Description:

Inclusion criteria:

  1. Participants are moderate to severe dry eye patients aged more than 18 years of age
  2. Oxford staining scores of more than five.
  3. OSDI scores of more than 0.1

Outcome measurements:

Main parameter is staining score (corneal + conjunctival) Other parameter is OSDI score, symptom of ocular surface discomfort score, number of daily artificial tear needed, TBUT, Schirmer I score, cytokines level & markers Safety parameters: VA, IOP, cyclosporin level


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • moderate to severe dry eye

Exclusion Criteria:

  • lid anomaly, previous CsA use
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00704275

Contact: Vilavun Puangsricharern, MD 66-2256-4424
Contact: Anyanee Charoensri, MD 66-8464-70202

OPD Chulalongkorn University Hospital Active, not recruiting
Bangkok, Thailand, 10330
OPD Chulalongkorn University Hospital Recruiting
Bangkok, Thailand
Contact: Vilavun Puangsricharern, MD         
Sponsors and Collaborators
Chulalongkorn University
  More Information

Responsible Party: Vilavun Puangsricharern/Ass. Prof in Ophthalmology, Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University Identifier: NCT00704275     History of Changes
Other Study ID Numbers: 391/48 
Study First Received: June 20, 2008
Last Updated: June 23, 2008
Health Authority: Thailand: Khon Kaen University Ethics Committee for Human Research

Keywords provided by Chulalongkorn University:
dry eye

Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Conjunctival Diseases
Eye Diseases
Corneal Diseases
Lacrimal Apparatus Diseases
Anti-Inflammatory Agents
Ophthalmic Solutions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors
Pharmaceutical Solutions processed this record on October 21, 2016